Profil bibliographique

Mark Ainsworth

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

446Publications signalées

21721Citations signalées

3Affiliations récentes

Institutions déclarées

University of Southern Denmark Brown University Odense University Hospital

Domaines associés

Advanced Numerical Methods in Computational MathematicsInflammatory Bowel DiseaseNumerical methods in engineeringElectromagnetic Simulation and Numerical MethodsMicroscopic Colitis

Publications récentes

Accès ouvert 2026 articleOpenAlex

Proactive Tight Monitoring of Patients with Inflammatory Bowel Disease in Biological Therapy: A Controlled Clinical Study (TIME IT)

Katrine Risager Christensen, Osamah S. A. Al-Obaidi, Sine Buhl, Johan F. Ilvemark et autres

0 citationsJournal of Clinical Medicine

2026 conference-abstractOpenAlex

Sa1507 HIGH BASELINE INFLIXIMAB CLEARANCE IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS PREDICTS NEED FOR DOSE INTENSIFICATION TO ACHIEVE TREATMENT OUTCOMES COMPARABLE TO PATIENTS WITH LOW CLEARANCE

Mathilde J. Nissen, Frederik Ørtoft, Pernille D. Ovesen, Mark Ainsworth et autres

0 citationsGastroenterology

2026 conference-abstractOpenAlex

Sa1507 HIGH BASELINE INFLIXIMAB CLEARANCE IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS PREDICTS NEED FOR DOSE INTENSIFICATION TO ACHIEVE TREATMENT OUTCOMES COMPARABLE TO PATIENTS WITH LOW CLEARANCE

Mathilde J. Nissen, Frederik Ørtoft, Pernille D. Ovesen, Mark Ainsworth et autres

0 citationsGastrointestinal Endoscopy

2026 conference-abstractOpenAlex

Su1512 EXTRACELLULAR MATRIX BIOMARKERS MAY AID IN CHOICE OF ADVANCED THERAPY SEQUENCING TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Camilla Frimor, Marta Sorokina Alexdóttir, Thomai Tsapanou-Katranara, Letizia Satriano et autres

0 citationsGastroenterology

2026 conference-abstractOpenAlex

Sa1544 EXTRACELLULAR MATRIX-DERIVED BIOMARKERS OF MUCOSAL DAMAGE AND NEUTROPHIL ACTIVITY ARE ASSOCIATED WITH VEDOLIZUMAB FAILURE IN ANTI-TNF EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS

Marta Sorokina Alexdóttir, Camilla Frimor, Thomai Tsapanou-Katranara, Letizia Satriano et autres

0 citationsGastrointestinal Endoscopy

2026 conference-abstractOpenAlex

Tu1475 THERAPEUTIC DRUG MONITORING OF USTEKINUMAB AND VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EXPANDING FLEXIBILITY THROUGH PHARMACOKINETIC-PHARMACODYNAMIC TIME-BASED THRESHOLDS

Ella S. Widigson, Camilla Frimor, Casper Steenholdt, Zrinka Duvnjak et autres

0 citationsGastroenterology

2026 conference-abstractOpenAlex

Sa1544 EXTRACELLULAR MATRIX-DERIVED BIOMARKERS OF MUCOSAL DAMAGE AND NEUTROPHIL ACTIVITY ARE ASSOCIATED WITH VEDOLIZUMAB FAILURE IN ANTI-TNF EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS

Marta Sorokina Alexdóttir, Camilla Frimor, Thomai Tsapanou-Katranara, Letizia Satriano et autres

0 citationsGastroenterology

2026 conference-abstractOpenAlex

Su1513 EXTRACELLULAR MATRIX BIOMARKERS MAY AID CHOICE OF ADVANCED THERAPY SEQUENCING TO VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Camilla Frimor, Marta Sorokina Alexdóttir, Thomai Tsapanou-Katranara, Letizia Satriano et autres

0 citationsGastroenterology

2026 conference-abstractOpenAlex

Sa1480 GENETIC FACTORS INFLUENCING RISK OG ANTI-DRUG ANTIBODY FORMATION IN INFLAMMATORY BOWEL DISEASE

Frederikke B. Culmsee-Holm, Emil Buhl, Mads T. Kraaer, Casper Steenholdt et autres

0 citationsGastrointestinal Endoscopy

2026 articleOpenAlex

629 HEALTH-RELATED QUALITY OF LIFE IMPAIRMENT PRECEDES MANIFESTATION OF CLINICAL RELAPSE BY SEVEN WEEKS IN PATIENTS WITH CROHN’S DISEASE DISCONTINUING INFLIXIMAB

Mathilde J. Nissen, Prabhpreet K. Gill, Sine Buhl, Jørn Brynskov et autres

0 citationsGastroenterology

2026 articleOpenAlex

629 HEALTH-RELATED QUALITY OF LIFE IMPAIRMENT PRECEDES MANIFESTATION OF CLINICAL RELAPSE BY SEVEN WEEKS IN PATIENTS WITH CROHN’S DISEASE DISCONTINUING INFLIXIMAB

Mathilde J. Nissen, Prabhpreet K. Gill, Sine Buhl, Jørn Brynskov et autres

0 citationsGastrointestinal Endoscopy

2026 conference-abstractOpenAlex

Tu1475 THERAPEUTIC DRUG MONITORING OF USTEKINUMAB AND VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EXPANDING FLEXIBILITY THROUGH PHARMACOKINETIC-PHARMACODYNAMIC TIME-BASED THRESHOLDS

Ella S. Widigson, Camilla Frimor, Casper Steenholdt, Zrinka Duvnjak et autres

0 citationsGastrointestinal Endoscopy

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.